TREATMENT OF NON-SMALL-CELL LUNG CANCER WITH AIDI INJECTION BASED ON NETWORK PHARMACOLOGY

Abstract

This study aimed to determine the bioactive compounds, core genes, and pharmacological mechanisms underlying the effects of Aidi injection (ADI) in non‐small‐cell lung cancer (NSCLC), and to provide a further research directions.The bioactive compounds of ADI were obtained from the Traditional Chinese Medicine Systems Pharmacology Database and the Traditional Chinese Medicines Integrated Database, whiletargets related to these bioactive compounds and NSCLC were obtained from the GEO database. Cytoscape software was used to construct ingredients–protein-targets–pathway networks.Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway analyses and network analysis were performed to investigate potential mechanisms underlying the effects of ADI on NSCLC.This study screened 45 bioactive compounds and 38 major proteins of ADI as potential agents that can act against NSCLC. The results revealed the following potential therapeutic targets of ADI in the treatment of NSCLC: FOS, VEGFA, EGFR, JUN, MMP9, IL2, STAT1, CASP1, NFKBA, and CDK2. The potential mechanisms via which ADI acts against NSCLC are closely related to the inhibition of apoptosis and the activation of signaling pathways.This study has revealed the multicompound, multitarget, and multichannel characteristics of ADI. This provides novel insight into further research investigations of the mechanism of ADI in NSCLC treatment.